SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is seeing heightened investor attention amid escalating Middle East tensions, following reports of a drone strike on Saudi Arabia's largest oil refinery and fears over the Strait of Hormuz. The community is actively discussing its potential for a significant short squeeze and a parabolic price run, drawing comparisons to past oil rallies driven by geopolitical events.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp. (BATL) is soaring amidst intense discussions surrounding escalating geopolitical tensions impacting Middle Eastern oil supply and shipping, leading to a surge in crude prices. The low-float oil producer is a focal point for traders anticipating a significant short squeeze due to high short interest and heightened market volatility.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing a massive price surge driven by strong earnings and bullish guidance for its 800G transceiver demand from hyperscale data centers, leading to multiple analyst upgrades in the optical networking sector. The community is keenly debating whether the stock's parabolic move reflects genuine long-term potential in AI infrastructure or if it's an overvalued pump-and-dump susceptible to dilution from a recent stock offering.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as the critical role of photonics in AI infrastructure draws intensified investor focus, evidenced by recent significant institutional stakes, though community sentiment remains split between high conviction in its optical interconnect technology and impatience for tangible commercialization ahead of the upcoming OFC conference.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

United States Oil Fund (USO) is surging amidst heightened geopolitical tensions from reported U.S.-Israeli strikes on Iran and subsequent retaliatory attacks, driving community discussion around severe oil supply disruptions if the Strait of Hormuz remains impacted, with many anticipating a significant price surge.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is trending sharply lower after the FDA indicated that Phase I/II data for its Huntington's disease gene therapy, AMT-130, are insufficient for approval, recommending a larger, sham-controlled Phase III trial. The community is actively debating this regulatory setback, questioning the FDA's "moving goalposts" and commitment to accelerating treatments for rare diseases.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending following a solid Q4 earnings beat and a new five-year LNG supply agreement with Trafigura, reinforcing its strong growth trajectory. The community is actively discussing the stock's significant undervaluation compared to its rapidly expanding LNG capacity, emphasizing its strategic advantage in the spot market amid escalating geopolitical tensions in the Strait of Hormuz, which could further drive up global LNG prices and potentially trigger a short squeeze.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Escalating geopolitical tensions in the Middle East, marked by drone strikes on key energy facilities and reports of shipping disruptions in the Strait of Hormuz, are fueling widespread speculation about rapidly rising oil prices. The community is largely bullish on Exxon Mobil, viewing it as a direct beneficiary of the heightened risk premium and anticipating significant upside for the broader energy sector.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is capturing market attention as escalating US-Iran tensions and potential disruptions in the Strait of Hormuz drive strong safe-haven flows, leading community discussion around gold's role as a critical hard asset during geopolitical uncertainty.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending due to a strategic agreement with NVIDIA, which includes a significant investment and commitment for advanced optical components, positioning the company as a key player in the expanding AI data center infrastructure, while community discussions highlight both significant upside and concerns about its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

Shares of Inozyme Pharma, Inc. (INZY) rocketed 179% on Friday after BioMarin Pharmaceutical (BMRN) agreed to <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.inozyme.com/news-releases/news-release-details/biomarin-strengthens-enzyme-therapy-business-acquisition-inozyme">acquire</a> the company for $270 million.Under the deal, BioMarin will acquire Inozyme for $4 per share in an all-cash transaction. The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.BioMarin will commence a cash tender to acquire all of Inozyme's outstanding shares. A majority of the outstanding shares must be tendered for its consummation.Inozyme's Board of Directors unanimously recommended that shareholders tender their shares in the offer.Following the successful completion of the tender offer, a wholly-owned subsidiary of BioMarin will merge with Inozyme. The transaction is expected to close in the third quarter of 2025.BioMarin said that it expects the acquisition to strengthen its enzyme therapies portfolio.Inozyme’s late-stage enzyme replacement therapy, INZ-701, is currently being assessed for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 deficiency (ENPP1), a rare genetic disorder caused by mutations in the ENPP1 gene, leading to loss of ENPP1 enzymatic activity. Currently, there are no approved therapies for ENPP1 Deficiency, Inozyme said.BioMarin CEO Alexander Hardy said that the company will continue to evaluate both external and internal innovation going forward.“We are in a strong financial position to bring in additional assets as we accelerate the development of medicines for patients with significant unmet need," he said.On Stocktwits, retail sentiment around Inozyme jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_12_31_33_PM_png_8f9ddbb20d.webp" alt="INZY's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits" width="628" height="60"><figcaption>INZY's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure>For BioMarin, retail sentiment around the company fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_12_32_33_PM_png_3cde3c49bc.webp" alt="BMRN's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>BMRN's Sentiment Meter and Message Volume as of 12:30 p.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/INZY">INZY stock</a> has gained by 39% this year but has fallen by nearly 16% over the past 12 months.<a href="https://stocktwits.com/symbol/BMRN">BMRN stock</a> is trading nearly 2% higher as of Friday noon.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/volkswagen-shareholders-flag-governance-issues-at-car-company/chiwBRDRbnU">Volkswagen Shareholders Flag Governance Issues At Carmaker, Says Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens

The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.

Inozyme Stock Rockets 178% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens

Equity

The deal's per-share price consideration implies an 182% premium to Inozyme’s closing price of $1.42 on Thursday.


Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Inozyme Pharma Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

INZY
Inozyme Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INZY News

INZYInozyme Pharma Inc